José A Castro-Rodriguez, Eleanor N Fish, Samuel T Montgomery, Tobias R Kollmann, Carolina Iturriaga, Casey Shannon, Yuliya Karpievitch, Joseph Ho, Virginia Chen, Robert Balshaw, Rym Ben-Othman, Radhouane Aniba, Francisca Gidi-Yunge, Lucy Hartnell, David G Hancock, Guillermo Pérez-Mateluna, Marcela Urzúa, Scott J Tebbutt, Diego García-Huidobro, Cecilia Perret, Arturo Borzutzky, Stephen M Stick
BACKGROUND: Accumulating evidence indicates that an early, robust type 1 interferon (IFN) response to SARS-CoV-2 is important in determining COVID-19 outcomes, with an inadequate IFN response associated with disease severity. Our objective was to examine the prophylactic potential of IFN administration to limit viral transmission. METHODS: A cluster randomised open label clinical trial was undertaken to determine the effects of pegylated IFNβ-1a administration on SARS-CoV-2 household transmission between December 3rd, 2020 and June 29th, 2021...
August 2023: EClinicalMedicine